Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12761610 | 0.85 | KMT2A (0.59) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL4634027 | 0.84 | KMT2A (0.58) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL7743458 | 0.83 | KMT2A (0.57) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL31652454 | 0.82 | KMT2A (0.58) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL30106235 | 0.82 | KMT2A (0.58) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL14008332 | 0.82 | KMT2A (0.64) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL29904323 | 0.82 | KMT2A (0.64) | KMT2AEPHX2CASP3 | |
| SCHEMBL31546963 | 0.81 | KMT2A (0.57) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL13525077 | 0.81 | KMT2A (0.73) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL3140809 | 0.81 | KMT2A (0.73) | KMT2AEPHX2CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404664-B2 | Phosphonated Rifamycins and uses thereof for the prevention and treatment of bone and joint infections | TARGANTA THERAPEUTICS, INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-20110263534-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263534-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | KMT2A 4393/4885EPHX2 3510/4885CASP3 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.